- A young British biotech company has found a way to turn one of medicine’s most unpredictable breakthroughs into a repeatable engineering process.
Ternary Therapeutics has raised £3.6m in seed funding to scale a new artificial intelligence platform designed to create “molecular glue” drugs. The round was led by European venture firm daphni, with participation from Pace Ventures, i&i Biotech Fund and the UK Innovation & Science Seed Fund which is managed by Future Planet Capital.
Molecular glues are small drug molecules that force two proteins inside a cell to stick together. When they bind, they can switch off harmful proteins or restore lost function. In theory, this approach could treat diseases that have defeated traditional drug discovery, including chronic inflammatory and neuroinflammatory conditions.
In practice, molecular glues have largely been discovered by accident. Scientists often stumble across them rather than design them.
Ternary exists to change that. Founded in November 2024, the London-based company has built an integrated platform that combines artificial intelligence, physics-based modelling and laboratory testing to design molecular glues deliberately and systematically.
The software predicts how proteins move and interact at the atomic level. It then proposes small molecules that could bring two specific proteins together in a controlled way. Those predictions are tested rapidly in the lab, and the results are fed back into the system to improve the next design cycle.
The result, the company says, is a closed loop between computation and experiment that replaces chance with engineering.
The platform has already produced a pipeline of preclinical drug candidates aimed at inflammatory diseases where existing treatments are limited or ineffective. Ternary has also signed multiple research collaborations with pharmaceutical and specialist biotechnology companies.
“For decades, molecular glues have been one of the most powerful ideas in drug discovery, but also one of the least predictable,” he said. “We have shown that by combining physics-informed AI with tight experimental feedback, we can design these molecules intentionally rather than waiting to discover them by luck. The new capital will allow Ternary to expand our scientific and computational teams and advance our lead programmes towards clinical development.”
As part of its next phase, Ternary has appointed Dr Ian Taylor to its Board of Directors. Dr Taylor is a veteran of targeted protein degradation research and recently retired as President of Research and Development at Arvinas.
During his nine years at the company, he oversaw six Investigational New Drug submissions. One of those programmes, the estrogen receptor PROTAC Vepdegestrant, is currently under review by the US Food and Drug Administration and could become the first approved therapy of its kind.
Earlier in his career, Dr Taylor held senior roles at Pfizer Oncology and Bayer Pharmaceuticals. He earned his PhD in Molecular Biology and Genetics from Harvard University and completed postdoctoral research under Nobel laureate Harold Varmus.
“Designing molecular glues predictably is one of the hardest challenges in modern drug discovery,” he said. “It requires deep expertise across machine learning, physics and experimental biology. Ternary has built a platform that integrates all three in a disciplined and scalable way.”
The investment follows the recent launch of Daphni Blue, a €260 million fund focused on science-led deep technology companies addressing major societal challenges.
For Ternary, the ambition is straightforward. If molecular glues can be designed reliably, then proteins once considered undruggable may become viable targets. That would expand the reach of small molecule medicines into areas where biology has so far outpaced chemistry.
The company now faces the next test common to all early-stage biotech ventures. It must show that its engineered discoveries can translate into safe and effective medicines in patients.
© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, 1 Scott Place, 2 Hardman Street, Manchester, M3 3AA.